case / 31 Aug 2022
Setterwalls has assisted Enzymatica AB in connection with a rights issue of SEK 74.7 million
Enzymatica AB is a life science company that develops and sells health products mainly to treat diseases and symptoms in the upper respiratory tract. The products are based on a barrier technology that includes marine enzymes with unique properties. The company’s first product is the medical device product ColdZyme®, a mouth spray for common colds. The product has been launched in about 30 markets on four continents. The company is headquartered in Lund and is listed on Nasdaq First North Growth Market.